Guardian Bio Analysis: $500K Raised
What is Guardian Bio?
Guardian Bio combines regenerative medicine with immunotherapy to restore anti-cancer immunity in late-stage solid tumor patients through innovative dendritic cell therapy.
Product Features & Capabilities
- Guard-cDC1s generated from patient’s own stem cells, capable of restoring dysfunctional antigen presentation, stimulate against multiple targets simultaneously, activate various effector cells.
How much Guardian Bio raised
1: - $500,000
August 22, 2022Lead Investor: Y Combinator
Who are the founders of Guardian Bio
AZ
Ananya Zutshi
Co-Founder and CEO
RB
Ricky Barrett
Co-Founder and CSO
Market Focus
Guardian Bio primarily focuses on the biotechnology industry, specifically in the fields of regenerative medicine and immunotherapy aimed at restoring anti-cancer immunity in late-stage solid tumor patients.
Investors
- Creative Destruction Lab
- Amal K
- Brazen Capital
- Fundament
- James Jarrett
- Y Combinator
- Phoenix Investment Club
Competitors Overview
Guardian Bio operates in the competitive landscape of cancer immunotherapy and regenerative medicine, particularly focusing on late-stage solid tumors. Its main competitors include:
- Amgen: Known for its advancements in monoclonal antibodies, Amgen is a significant player in the oncology mark
See something that needs updating? Suggest edits to this profile.